2. Search Result
Search Result
Results for "

IFNγ

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

7

Peptides

3

Inhibitory Antibodies

5

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4717A
    IFN-γ Antagonist 1 acetate

    		IFNAR Inflammation/Immunology
    IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate is an antagonist of interferon γ (IFN γ). IFN-γ Antagonist 1 inhibits IFN-γ induced HLR/DR antigen expression in Colon 205 cells with an IC50 value of approximately 35 μM. IFN-γ Antagonist 1 has potential applications in immune regulation .
    <em>IFN-γ</em> Antagonist 1 acetate
  • HY-P99191
    Emapalumab

    NI-0501

    		 IFNAR Inflammation/Immunology
    Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
    Emapalumab
  • HY-153446
    Tegeprotafib

    PTPN2/1-IN-1

    		 Phosphatase Cancer
    Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC50s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively .
    Tegeprotafib
  • HY-W013523
    2-NP
    2 Publications Verification

    		 STAT Cancer
    2-NP is a selective enhancer of STAT1 transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells .
    2-NP
  • HY-P4717
    IFN-γ Antagonist 1

    		IFNAR Inflammation/Immunology
    IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) is an antagonist of interferon γ (IFN γ). IFN-γ Antagonist 1 inhibits IFN-γ induced HLR/DR antigen expression in Colon 205 cells with an IC50 value of approximately 35 μM. IFN-γ Antagonist 1 has potential applications in immune regulation .
    <em>IFN-γ</em> Antagonist 1
  • HY-161016
    TNF/IFN-γ-IN-1

    		TNF Receptor IFNAR Neurological Disease
    TNF/IFN-γ-IN-1 (compound TGA) is a dual inhibitor of TNF and IFN-γ. TNF/IFN-γ-IN-1 can used in study Alzheimer’s disease .
    TNF/IFN-γ-IN-1
  • HY-154387
    1-Isopropyltryptophan

    1-IsoPT

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    1-Isopropyltryptophan (1-IsoPT) is a IDO1 inhibitor. 1-Isopropyltryptophan decreases the expression of IFN-γ stimulated ID0-1 and ID0-2 mRNA .
    1-Isopropyltryptophan
  • HY-106755
    Tucaresol

    BWA589C

    		 HIV Infection Cancer
    Tucaresol is an orally bioavailable immunopotentiatory drug that show to enhance T-helper-cell activity, with the induction of increased IL-2 and IFN-γ levels in mice and humans. Tucaresol has anti-HIV effect .
    Tucaresol
  • HY-N3312
    Matairesinol

    		Endogenous Metabolite Infection
    Matairesinol confers anti-allergic effects in an allergic dermatitis mouse model. DfE-induced changes in IL-4 and IFN-γ mRNA expression in the ears of NC/Nga mice were reversed by matairesinol application .
    Matairesinol
  • HY-120559
    GSK-2250665A

    		Itk Inflammation/Immunology
    GSK-2250665A (Compound 13) is a selective Itk inhibitor with a pKi of 9.2.
    GSK-2250665A
  • HY-150741
    ODN 2216
    1 Publications Verification

    		 Toll-like Receptor (TLR) IFNAR Interleukin Related Infection Inflammation/Immunology Cancer
    ODN 2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4 + T cells .
    ODN 2216
  • HY-150741C
    ODN 2216 sodium

    		Toll-like Receptor (TLR) Cancer
    ODN?2216 sodium is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN?2216 sodium induces high amounts of IFN-α and IFN-β. ODN 2216 sodium induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 sodium stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 sodium can activate NK cells and promote IFN-γ production of TCR-triggered CD4 + T cells .
    ODN 2216 sodium
  • HY-156711
    Ternatumoside II

    		Others Inflammation/Immunology
    Ternatumoside II is a flavonoid glycoside that can be isolated from R. crenulata. Ternatumoside II can stimulate IFN-γ expression. Ternatumoside II has radical-scavenging activities (IC50s: 260.5 μM and 320.2 μM for DPPH and ABTS) .
    Ternatumoside II
  • HY-134371
    IL-17 modulator 2

    		Interleukin Related Inflammation/Immunology
    IL-17 modulator 2 (compound 159) is an orally active modulator of IL-17. IL-17 modulator 2 significantly reduces IL-6, IFN-γ, and edema. IL-17 modulator 2 can used in study arthritis .
    IL-17 modulator 2
  • HY-160026
    IL-17 modulator 8

    		Interleukin Related Inflammation/Immunology
    IL-17 modulator 8 (compound 286) is an orally active modulator of IL-17. IL-17 modulator 8 significantly reduces IL-6, IFN-γ, and edema. IL-17 modulator 8 can used in study arthritis .
    IL-17 modulator 8
  • HY-160028
    IL-17 modulator 9

    		Interleukin Related Inflammation/Immunology
    IL-17 modulator 9 (compound 453) is an orally active modulator of IL-17. IL-17 modulator 9 significantly reduces IL-6, IFN-γ, and edema. IL-17 modulator 9 can used in study inflammation .
    IL-17 modulator 9
  • HY-106359
    Delmitide

    RDP-58

    		 TNF Receptor IFNAR Reactive Oxygen Species Infection Inflammation/Immunology Cancer
    Delmitide (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis .
    Delmitide
  • HY-152851
    Izumerogant

    IMU-935

    		 ROR Others
    Izumerogant (IMU-935) is an inverse agonist of retinoid-related orphan receptor-gamma (RORγ). Izumerogant (compound 123) also potently inhibits IL-17A, IL-17F and IFN-γ activity with IC50s <50 nM .
    Izumerogant
  • HY-106359A
    Delmitide acetate

    RDP-58 acetate

    		 TNF Receptor IFNAR Reactive Oxygen Species Cancer
    Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide acetate inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide acetate can be used for the research of ulcerative colitis .
    Delmitide acetate
  • HY-115734
    Phenylpyropene C

    S14-95

    		 Acyltransferase Inflammation/Immunology
    Phenylpyropene C (S14-95), a JAK/STAT pathway inhibitor, can inhibit IFN-γ mediated expression of the reporter gene (IC50=5.4~10.8 μM). Phenylpyropene C also is an inhibitor of acyl-CoA, with an IC50 of 16.0 μM .
    Phenylpyropene C
  • HY-157937
    VISTA-IN-3

    		IFNAR Cancer
    VISTA-IN-3 (Compound A4) is a potent VISTA small molecule inhibitor with a KD value of 0.49 μM. VISTA-IN-3 can induce the release of IFN-γ cytokines. VISTA-IN-3 synergistically enhances anti-cancer activity with PD-L1 antibody .
    VISTA-IN-3
  • HY-111745
    Tyk2-IN-5

    		JAK Inflammation/Immunology
    Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a Ki value of 0.086 nM for Tyk2 JH2 and an IC50 value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .
    Tyk2-IN-5
  • HY-155193
    XY-52

    		Others Inflammation/Immunology
    XY-52 (Compound 32) is a Stimulation-2 (ST2) inhibitor, with an IC50 value of 5.68 μM in AlphaLISA assay, and 4.59 μM in HEK-Blue assay. XY-52 increases proinflammatory T-cell proliferation. XY-52 reduces the plasma sST2 and IFNγ biomarkers in the graft versus host disease (GVHD) mice model .
    XY-52
  • HY-133897
    (Rac)-Indoximod
    1 Publications Verification

    1-Methyl-DL-tryptophan; (Rac)-NLG-8189

    		 Indoleamine 2,3-Dioxygenase (IDO) Apoptosis Inflammation/Immunology Cancer
    (Rac)-Indoximod (1-Methyl-DL-tryptophan) is an indoleamine 2,3-dioxygenase (IDO) inhibitor. Co-treatment with IFN-γ and (Rac)-Indoximod markedly reduces the activity of human cardiac myofibroblasts (hCMs) expressing α-SMA and induces apoptosis through up-regulating the IRF-1, Fas, and FasL genes .
    (Rac)-Indoximod
  • HY-P99032
    Monalizumab
    1 Publications Verification

    IPH2201

    		 Checkpoint Kinase (Chk) IFNAR Inflammation/Immunology Cancer
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
    Monalizumab
  • HY-B0446
    Naphazoline hydrochloride

    Naphthazoline hydrochloride

    		 Adrenergic Receptor TNF Receptor Interleukin Related VEGFR Cardiovascular Disease Inflammation/Immunology
    Naphazoline (Naphthazoline) hydrochloride is a potent α-adrenergic receptor agonist. Naphazoline hydrochloride reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline hydrochloride reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF。Naphazoline hydrochloride can be used for non-bacterial conjunctivitis research .
    Naphazoline hydrochloride
  • HY-19676
    Pralnacasan

    VX-740; HMR 3480

    		 Caspase Inflammation/Immunology
    Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a Ki of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment .
    Pralnacasan
  • HY-111326
    Naphazoline

    Naphthazoline

    		 Adrenergic Receptor TNF Receptor Interleukin Related VEGFR Cardiovascular Disease Inflammation/Immunology
    Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF。Naphazoline can be used for non-bacterial conjunctivitis research .
    Naphazoline
  • HY-N9965
    2'-Fucosyllactose

    2'-FL

    		 TNF Receptor Interleukin Related Infection Inflammation/Immunology
    2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines .
    2'-Fucosyllactose
  • HY-131968
    BMS-986202

    		JAK Cytochrome P450 Inflammation/Immunology
    BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .
    BMS-986202
  • HY-111326A
    Naphazoline nitrate

    Naphthazoline nitrate

    		 Adrenergic Receptor TNF Receptor Interleukin Related VEGFR Cardiovascular Disease Inflammation/Immunology
    Naphazoline (Naphthazoline) nitrate is an α-adrenergic receptor agonist. Naphazoline nitrate reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline nitrate reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF。Naphazoline nitrate can be used for non-bacterial conjunctivitis research .
    Naphazoline nitrate
  • HY-149356
    PD-1/PD-L1-IN-31

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .
    PD-1/PD-L1-IN-31
  • HY-161335
    HPK1-IN-43

    		MAP4K Interleukin Related IFNAR Cancer
    HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC50 value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .
    HPK1-IN-43
  • HY-N0407
    Picroside I

    6'-Cinnamoylcatalpol

    		 STAT Inflammation/Immunology
    Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II . Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ .
    Picroside I
  • HY-107390A
    AX-024 hydrochloride
    1 Publications Verification

    		 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology
    AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
    AX-024 hydrochloride
  • HY-107390
    AX-024
    1 Publications Verification

    		 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology
    AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
    AX-024
  • HY-137295
    Ingenol 3,20-dibenzoate

    		PKC Apoptosis Inflammation/Immunology
    Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells .
    Ingenol 3,20-dibenzoate
  • HY-144649
    PD-1/PD-L1-IN-24

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC50 value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs .
    PD-1/PD-L1-IN-24
  • HY-P4846
    Ac-Pro-Gly-Pro-OH

    		CXCR Inflammation/Immunology
    Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as CXCR2 agonist. Ac-Pro-Gly-Pro-OH elicits bactericidal activity and inhibits lung inflammation, reducing immune cell apoptosis. Ac-Pro-Gly-Pro-OH enhances the production of type 1 cytokines (IFN-γ and IL-12) but inhibits the production of proinflammatory cytokines. Ac-Pro-Gly-Pro-OH has the potential for the research of sepsis .
    Ac-Pro-Gly-Pro-OH
  • HY-161255
    3,4-DAA

    		NO Synthase Inflammation/Immunology
    3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4 +CD25 + T cells expression . 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide .
    3,4-DAA
  • HY-150725
    ODN 1585

    		IFNAR TNF Receptor Infection Inflammation/Immunology Cancer
    ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
    ODN 1585
  • HY-P99499
    Cetrelimab

    JNJ 63723283; JNJ 3283

    		 PD-1/PD-L1 Interleukin Related TNF Receptor Cancer
    Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
    Cetrelimab
  • HY-19744
    T6167923
    Maximum Cited Publications
    11 Publications Verification
    T6167923 is a selective inhibitor of MyD88-dependent signaling pathways. T6167923 directly binds to Toll/IL1 receptor (TIR) domain of MyD88 and disrupts MyD88 homodimeric formation. T6167923 inhibits NF-κB driven Staphylococcus enterotoxin AP (SEAP) activity, and improves anti-inflammatory activity with IC50s of 2.7  μM, 2.9 μM, 2.66 μM and 2.66 μM for IFN-γ, IL-1β, IL-6 and TNF-α, respectively .
    T6167923
  • HY-155580
    MAO A/HSP90-IN-2

    		Monoamine Oxidase HSP Cancer
    MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape [1].
    MAO A/HSP90-IN-2
  • HY-113953
    Z-Asp-CH2-DCB

    		Caspase Apoptosis Inflammation/Immunology
    Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development .
    Z-Asp-CH2-DCB
  • HY-151262
    JAK-IN-23

    		JAK STING NF-κB STAT Inflammation/Immunology
    JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) .
    JAK-IN-23

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: